following a full submission:
bortezomib (Velcade®) is accepted for restricted use within NHS Scotland.
Indication under review: In combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
SMC restriction: use as triple therapy in combination with dexamethasone and thalidomide.
Bortezomib, used in combination with dexamethasone and thalidomide for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation improved response rates compared with a dual combination regimen.
Download detailed advice155KB (PDF)
Medicine details
- Medicine name:
- bortezomib (Velcade)
- SMC ID:
- 927/13
- Indication:
- In combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 January 2014